Suchergebnisse - "Brufsky, Adam"

PubPharm (9)

1

Less is more? De-intensification of therapy for early-stage HER2-positive breast cancer

enthalten in: The lancet / Oncology | 2017

von Mathew, A. | Brufsky, A.

2

Is there room for bevacizumab in metastatic breast cancer?

enthalten in: The lancet / Oncology | 2016

von Brufsky, A.

3

Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial

enthalten in: The lancet / Oncology | 2015

von Bear, H. | Tang, G. | Rastogi, P. | +18

4

Length of chemotherapy and use of bevacizumab for breast cancer

enthalten in: The lancet / Oncology | 2014

von Brufsky, A.

5

The bone substudy of MA.27: does bone make a difference?

enthalten in: The lancet / Oncology | 2014

von Mathew, A. | Brufsky, A.

6

Treatment of HER2-positive breast cancer: looking backwards briefly

enthalten in: The lancet / Oncology | 2013

von Puhalla, S. | Brufsky, A.

7

Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial

enthalten in: The lancet / Oncology | 2013

von Robidoux, A. | Tang, G. | Rastogi, P. | +17

8

Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial

enthalten in: The lancet / Oncology | 2012

von Paterson, A. | Anderson, S. | Lembersky, B. | +17

9

Adjuvant bisphosphonates for early-stage breast cancer

enthalten in: The lancet / Oncology | 2011

von Brufsky, A.

1
[1]